Summit Therapeutics (stock symbol: SMMT) Logo in transparent PNG and SVG formats

Summit Therapeutics Logo large

Summit Therapeutics Logo icon format

Summit Therapeutics Logo large for dark backgrounds

Summit Therapeutics Logo icon format for dark backgrounds

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

  • Website domain: summittxinc.com
  • Employees: 105
  • Marketcap: $0.72 Billion USD

Page last updated on:

November 26th, 2022

Categories: